Idéal Investisseur
Français English
CAC 40 :
8 157,82 pts
-0.84%


Last updated : 24/04/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

Guerbet Strengthens its Executive Committee with a Dedicated Appointment in Interventional Radiology

Guerbet Group announces the appointment of François Convenant as Senior Vice-President of Interventional Radiology and his entry into the executive committee. This move aims to bolster the management of an activity described as strategic by the company.


Guerbet Strengthens its Executive Committee with a Dedicated Appointment in Interventional Radiology

Executive Committee Enhancement

François Convenant joins the Guerbet executive committee after joining the group in September 2018, the statement indicates. According to the company, he has international experience in the healthcare and medical devices field, gained within leading industry groups. Before joining Guerbet, he held leadership roles focused on innovation and growth in surgical solutions and interventional devices. His experience spans strategy, business development, and transformation, with an emphasis on improving clinical practices, the company specifies.

The Role of Interventional Radiology

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

Interventional radiology combines advanced imaging and minimally invasive therapeutic procedures, enabling the treatment of conditions such as cancers, vascular diseases, or chronic disorders, Guerbet explains. According to the group, this specialty offers benefits in terms of risk reduction, hospitalization duration, and patient recovery time. The company positions itself as a pioneer in this field and offers integrated solutions that include drugs, medical devices, services, and technologies, along with training programs for practitioners.

Company Profile

Guerbet employs 2,905 staff worldwide and has four research and development centers in France and the United States, according to the statement. The group allocates 9% of its revenue to research and development. Listed in compartment B of Euronext Paris, Guerbet reported a revenue of 841 million euros in 2024, according to the data provided by the company. The group presents itself as a global player in medical imaging, offering a range of pharmaceutical products, medical devices, and digital solutions for diagnostic and interventional imaging.

Related


Sector Industrie Pharmaceutique et Biotechnologie Industrie Pharmaceutique


Assurance vie

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit